Disruptive innovation is a priority for anyone seeking growth in today’s investment climate. Milltrust clients receive privileged access to thoroughly vetted opportunities across a range of risk/return profiles.
Despite British universities being consistently high in global rankings, Britain has historically struggled to raise sufficient capital to commercialise its world-class research. The British Innovation Fund supplies capital to support early stage spin out companies forming as a result of this research. The Fund invests into leading British University commercialisation companies and spin out companies emanating from these Universities.
The British Innovation Fund recognises the world-class science and technology development that is being carried out in many of Britain’s top universities. The Fund nurtures impactful, early-stage companies – helping them reach their full potential and guiding them to world-wide recognition and success.
The Fund carefully picks spin out companies from the established, in-house university commercialisation companies which the Fund has invested in – spin out companies that demonstrate a viable commercial business and are already generating revenue. This significantly reduces investment risks and enhances the probability of outsized returns for investors.
1) The academics at the universities will bring promising IP and commercially reliable ideas to the attention of the university commercialisation company.
2) The eyes and ears of the experienced technologists and venture capitalists at the commercialisation company view these ideas and invest into the most promising opportunities.
3) The investment advisory committee of the British Innovation Fund assesses the recommendations of the commercialisation companies before deploying capital.
Oxford Sciences Innovation (OSI) is the commercialisation partner of Oxford University’s sciences departments. Its vision is to turn a thousand years of world-beating science into the next generation of world-leading companies by linking Oxford’s research to the best human and financial capital.Learn More
Roslin Technologies is the technology commercialisation company of the University of Edinburgh’s Roslin Institute. Based at Easter Bush Campus, the largest concentration of animal science expertise in Europe, Roslin Technologies exists to deliver breakthrough commercial solutions in the Animal Health, Breeding/Genetics and Animal Nutrition space based on the expert agricultural research of the Institute.Learn More
PragmatIC, backed by Cambridge Innovation Capital, is a world leader in the manufacturing of ultra low cost flexible electronics, enabling the potential for trillions of smart objects that can engage with consumers and their environments. PragmatIC’s unique technology platform delivers flexible integrated circuits that are thinner than a human hair and can be easily embedded into everyday objects.Learn More
Attomarker, a spin out from the University of Exeter, is a digital health technology company which has developed a small, simple-to-use blood-testing device that can perform blood tests from a single pin-prick of blood, with results in around five minutes. This multi-patented technology collects the blood sample on a disposable credit-card sized chip which slots into a fully mobile device, docked to an iPhone. The iPhone camera visualises the blood tests which are then interpreted by the iPhone.Learn More
|Platform:||Milltrust International Managed Investments ICAV|
|Investment Manager:||Milltrust International LLP|
|Investment Adviser:||Milltrust Agricultural Investments Ltd|
|Structure:||Open-ended Investment Company|
|Strategy:||Commercialisation of research emerging out of UK universities|
|Inception Date:||25 November 2016|
|Share Classes:||Class (A), Class (B), Class (C), Class (D)|
|Performance Fee:||20% over Hurdle Rate|
|Subscription Terms:||10 years|
|Investor Types:||For Professional and Accredited Investors Only|
|Registered for Distribution in:||United Kingdom, Ireland|
|Administrator:||MUFG Alternative Fund Services (Ireland) Ltd.|
|Custodian:||Mitsubishi UFJ Investor Services & Banking (Luxembourg) S.A.|
Milltrust CerraCap II is a Global fund dedicated to early stage technology investments. The fund focuses on Enterprise (B2B) products and solutions in the emerging technology areas of Healthcare, AI and Cyber Security.
The fund reduces investment risk by maintaining one strategy since inception; targeting great teams with high growth characteristics. CerraCap makes great management better by personally introducing companies to Fortune 500 decision makers. The team call this model Sales and Scale where they industrialize innovation.
The fund is managed by Milltrust in Cayman feeding into a US partnership.
The team has worked together for an average of 10yrs. They have achieved over $500M in combined software sales and previously ran a highly successful corporate VC for a large tech company
Help sell portfolio companies into Fortune 500 enterprises. De-risking the early-stage model
“Enable Purchase Orders, not just introductions”
Collaboration with IT companies Fortune 500 clients and larger VCs
Unparalleled and ACTIVE Advisory board; providing leverage and access
GPs have 52 investments over seven years
Average valuation multiple across previous investments 9x
Viome is focused on disrupting healthcare by “making illness optional”. The Viome test is a breakthrough microbiome bacteria, epigenetics, epigenome and epigenomics technology. Chronic diseases are the fastest growing diseases all over the world. Viome has the potential to positively impact millions of people if not billions all around the world. Driven to create a future where illness is optional by identifying predictive biomarkers for diseases before any symptoms may occur so they can be prevented. The goal is to responsibly present facts in a way that can help anyone make decision. By applying Artificial Intelligence to the massive amount of high resolution microbiome and genetic data to find predictive biomarkers for chronic diseases.Learn More
In Quantix, Cerracap has assembled a powerhouse team with the ability, experience and the means to solve one of the most complex problems in the financial markets. Quantix has a singular focus: to build the most advanced commodity trading platform of its kind that analyzes more sources and types of data (social media, satellite images, real time news sources etc) and generates the most accurate predictions on price and volatility than anything else in the market. Sharpening The Competitive Edge For Commodities Traders, Quantix Processes Over 1200 Structured And Unstructured Parameters To Design Unbiased Trading Strategies In Real Time.Learn More
Founded in 2017 with focus on developing NLP+AI driven cognitive products for Enterprises. Developing AI based Natural Language Understanding and Automated Content Generation Platform. AutoR.ai is Nirveda’s 1st Authoring Assistant that helps content creators generate original content. Currently working in Stealth mode with one of world’s largest asset management company.Learn More
Censia is a people-obsessed company that believes talent is an organization’s most valuable asset. They exist to deliver the best talent to enterprises in the most efficient way possible through the power of intelligent technology. They’re transforming talent acquisition into a strategic partner that shapes the future of the company.Learn More
The fund is managed by CerraCap Ventures, headquartered in California with operations out of global hubs of tech innovation (San Francisco, Tel Aviv, and Bangalore).
The team at CerraCap Ventures are former UST Global execs from California, with a past track record returning a stellar 9x return since inception.
CerraCap Ventures also boasts a phenomenal advisory board including Vicente Fox, former President of Mexico, John C. Cushman, Chairman of Cushman & Wakefield, Richard P Crane Jr., Lawyer and Member of U.S. Department of Justice, and our own Simon Hopkins, amongst others